INO Inovio Pharmaceuticals Inc

Price (delayed)

$12.01

Market cap

$2.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.35

Enterprise value

$1.93B

Sector: Healthcare
Industry: Biotechnology

Highlights

The equity has soared by 74% from the previous quarter
Inovio Pharmaceuticals's debt has decreased by 26% QoQ and by 20% YoY
INO's quick ratio has surged by 71% year-on-year but it is down by 15% since the previous quarter
INO's net income has dropped by 57% year-on-year but it is up by 19% since the previous quarter
The gross profit has dropped by 67% year-on-year and by 23% since the previous quarter
INO's revenue has dropped by 67% year-on-year and by 23% since the previous quarter

Key stats

What are the main financial stats of INO
Market
Shares outstanding
169.41M
Market cap
$2.03B
Enterprise value
$1.93B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.21
Price to sales (P/S)
941.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
914.89
Earnings
Revenue
$2.11M
EBIT
-$169.52M
EBITDA
-$164.04M
Free cash flow
-$141.17M
Per share
EPS
-$1.35
Free cash flow per share
-$0.85
Book value per share
$1.93
Revenue per share
$0.01
TBVPS
$2.56
Balance sheet
Total assets
$437.81M
Total liabilities
$113.81M
Debt
$74.62M
Equity
$323.9M
Working capital
$335.8M
Liquidity
Debt to equity
0.23
Current ratio
9.14
Quick ratio
8.37
Net debt/EBITDA
0.63
Margins
EBITDA margin
-7,774%
Gross margin
100%
Net margin
-8,517.7%
Operating margin
-5,931.6%
Efficiency
Return on assets
-52.7%
Return on equity
-103%
Return on invested capital
-70.4%
Return on capital employed
-42.7%
Return on sales
-8,033.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INO stock price

How has the Inovio Pharmaceuticals stock price performed over time
Intraday
2.83%
1 week
-21.86%
1 month
33.44%
1 year
203.28%
YTD
35.71%
QTD
35.71%

Financial performance

How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$2.11M
Gross profit
$2.11M
Operating income
-$125.16M
Net income
-$179.73M
Gross margin
100%
Net margin
-8,517.7%
The gross profit has dropped by 67% year-on-year and by 23% since the previous quarter
INO's revenue has dropped by 67% year-on-year and by 23% since the previous quarter
INO's net income has dropped by 57% year-on-year but it is up by 19% since the previous quarter
The company's operating margin fell by 44% QoQ

Growth

What is Inovio Pharmaceuticals's growth rate over time

Valuation

What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.21
P/S
941.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
914.89
INO's EPS is up by 21% since the previous quarter but it is down by 14% year-on-year
The stock's price to book (P/B) is 81% less than its last 4 quarters average of 32.7 and 40% less than its 5-year quarterly average of 10.3
The equity has soared by 74% from the previous quarter
INO's revenue has dropped by 67% year-on-year and by 23% since the previous quarter
The P/S is 31% higher than the last 4 quarters average of 718.9

Efficiency

How efficient is Inovio Pharmaceuticals business performance
INO's ROE has soared by 53% from the previous quarter and by 43% YoY
INO's return on assets is up by 36% since the previous quarter and by 27% year-on-year
The company's return on invested capital rose by 27% QoQ but it fell by 6% YoY
INO's return on sales is down by 4.2% since the previous quarter

Dividends

What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INO.

Financial health

How did Inovio Pharmaceuticals financials performed over time
INO's current ratio has soared by 81% YoY but it is down by 9% QoQ
INO's quick ratio has surged by 71% year-on-year but it is down by 15% since the previous quarter
Inovio Pharmaceuticals's debt is 77% lower than its equity
The debt to equity has plunged by 92% YoY and by 57% from the previous quarter
Inovio Pharmaceuticals's debt has decreased by 26% QoQ and by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.